more featured news

Featured
Reality check: Unpacking the $150BGLP-1 market forecasts

Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric.

BIO International

DNB//Back Bay is pleased to sponsor the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

As Money Pours Into Weight Loss Drugs, Physicians Prioritize Efficacy, Access

With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.

Obesity Drug Development: Still Room to Grow
Nordic-American Healthcare Conference 2025 - Meeting Scheduling Now Available

This two-day equity conference is by invitation to institutional healthcare specialist and generalist investors, industry experts, corporate development, and healthcare executives. The NAHC includes sector-specific panel discussions with insights from DNB healthcare equity analysts, industry leaders, and investors.

Therapeutic Update: Bispecific Antibodies and the Blood-Brain-Barrier
 

featured transactions

Diversity Within Our Walls and Across Our Community

Back Bay is built on an appreciation of unique perspectives, a passion for creative approaches, and the ability to listen.

LEARN MORE